You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, June 2017
|
| DOI | 10.1186/s13195-017-0273-7 |
| Pubmed ID | |
| Authors |
Narjes Baazaoui, Khalid Iqbal |
| Abstract |
The use of neurotrophic factors to treat Alzheimer's disease (AD) is hindered by their blood-brain barrier impermeability, short half-life, and severe side effects. Peptide 021 (P021) is a neurotrophic/neurogenic tetra-peptide that was derived from the most active region of the ciliary neurotrophic factor (CNTF) by epitope mapping. Admantylated glycine was added to its C-terminal to increase its blood-brain barrier permeability and decrease its degradation by exopeptidases to make it druggable. Here, we report on the preventive effect of P021 in 3 × Tg-AD, a transgenic mouse model of AD. P021 was administered in the diet at 3 months, i.e., 6-9 months before any overt amyloid beta (Aβ) or tau pathology, and during the period of synaptic compensation, and was continued until 21 months in 3 × Tg-AD mice. The 3 × Tg-AD mice and wild-type (WT) mice were treated identically but with a vehicle-only diet serving as controls. The effects of P021 on neurogenesis, dendritic and synaptic markers, and cognitive performance were investigated. We found that P021 treatment was able to rescue dendritic and synaptic deficits, boost neurogenesis, and reverse cognitive impairment in 3 × Tg-AD mice. Availability of appropriate neurotrophic support during the period of synaptic compensation can prevent synaptic deficit and cognitive impairment, and P021 is a promising neurotrophic compound for this purpose. |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 25% |
| Student > Doctoral Student | 5 | 16% |
| Student > Ph. D. Student | 3 | 9% |
| Student > Bachelor | 1 | 3% |
| Other | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 12 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 9 | 28% |
| Business, Management and Accounting | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Environmental Science | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 15 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2017.
All research outputs
#4,215,480
of 22,985,065 outputs
Outputs from Alzheimer's Research & Therapy
#917
of 1,239 outputs
Outputs of similar age
#74,930
of 315,737 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#17
of 26 outputs
Altmetric has tracked 22,985,065 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,239 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.0. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,737 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.